Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onvansertib and paclitaxel in triple-negative metastatic breast cancer
NCT05383196Phase 2Active, not recruiting
- Sponsor
- Sbarro Health Research Organization
- Start
- Sep 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of onvansertib in triple-negative breast cancer (TNBC), sponsored by Sbarro Health Research Organization. Started Sep 2022; status: active, not recruiting.
02
Drugs
onvansertib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05383196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05383196.